{"url_path":"/sec/ganx/8-k/2026-08-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-094041-index.html","accession_number":"0001104659-26-094041","cik":"0001819411","ticker":"GANX","issuer_name":"Gain Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-094041-index.html","primary_entity_key":"0001819411","primary_entity_name":"Gain Therapeutics, Inc."},"word_count":295,"has_tables":true,"body_markdown":"Gain Therapeutics, Inc._August 11, 2026\n\n0001819411false00018194112026-08-112026-08-11\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**_______________**\n\n**FORM****8-K**\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\nDate of report (Date of earliest event reported):******August 11, 2026**\n\n**Gain Therapeutics, Inc.**\n\n(Exact Name of the Registrant as Specified in Charter)\n\n**Delaware**\n\n**001-40237**\n\n**85-1726310**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n\n(Commission\nFile Number)\n\n(IRS Employer\n\nIdentification No.)\n\n​\n\n**4800 Montgomery Lane****,****Suite 220**\n\n**Bethesda****,****Maryland********20814**\n\n(Address of principal executive offices) (Zip Code)\n\n**(****301****)****500-1556**\n\n(Registrant’s telephone number, including area code)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n**Title of each class**\n\n**Trading symbol(s)**\n\n**Name of exchange on which registered**\n\nCommon Stock, $0.0001 par value\n\nGANX\n\nThe NASDAQ Stock Market LLC\n\n​\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).\n\nEmerging growth company ☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n​\n\n​\n\n​"}